Search CommunityWalk:


TissueGene, Inc.

9605 Medical Center Drive, Suite 200
Rockville, MD 20850, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

TissueGene, Inc. is a biopharmaceutical company focused on regenerative medicine therapeutics. It was founded in 1997 by Kwan H. Lee and Woong Yeul Lee, with a mission to improve patient well-being and quality of life. The company aims to combine business savvy, medicine, research and information technology to effectively become one of the leaders in providing novel therapeutics to the health care industry.

TissueGene has developed a proprietary cell technology with applications in the treatment and regeneration of damaged tissues such as cartilage and bones. The company uses a form of cell mediated therapy to deliver therapeutic proteins to damaged tissue, which initiates rapid and permanent repair of injured tissue without the need for surgery. The technology consists of a novel method for inserting a therapeutic growth-factor gene into cells, culturing and stabilizing the genetically modified cells and then injecting the modified cells into damaged tissue via a hypodermic needle. The modified cells then secrete therapeutic growth-factor proteins directly into the injured site, acting like living protein factories, and induce tissue regeneration and repair. This cell technology can be applied in the treatment and regeneration of damaged tissues such as cartilage and bones.

TissueGene has a broad patent base portfolio covering the areas of regenerative orthopedic medicine. Its product TissueGene-C (TG-C), contains transforming growth factor (TGF-beta 1) gene indicated for the treatment of severe osteoarthritis of the knee.

TissueGene has research collaborations with Spine Institute, Columbia University, University of Pittsburgh, and Inha University. It also has agreements with PharmaVigilant, RheoGene, Inc., Kolon Life Science, Inc, AT-GC BioPharm, etc.